TMCnet News
Sarah Cannon Research Institute to Present Cancer Research Insights at American Society of Clinical Oncology's 51st Annual MeetingSarah Cannon Research Institute (SCRI) announced today it will present cancer research insights through 91 presentations selected by the American Society of Clinical Oncology (ASCO®) at the 51st annual meeting. Hosted in Chicago May 29 - June 2, it is the world's largest conference for cancer experts to review research data that is helping to better identify and treat various types of cancers. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20150521006370/en/ Sarah Cannon research leaders have abstracts accepted for presentation in four clinical science symposiums, 11 oral presentation sessions, 17 poster discussion sessions and 55 general posters, and are also presenting in three educational sessions and one community-based research forum. For full details on SCRI's presence at the meeting, visit sarahcannon.com/ASCO. "We look forward to sharing our research progress at this year's meeting, which includes 48 phase I abstracts and represents our collaborations with 46 pharmaceutical and biotech partners," said Chief Medical Officer and Executive Director, SCRI's Drug Development Program, Howard A. Burris III, MD. "From immunotherapies to agents that target genetic mutations, we continue to gain knowledge about which therapies are helping patients more effectively fight their cancer." Highlights of SCRI's research at the ASCO® Annual Meeting include a clinical science symposium presentation by David R. Spigel, MD, Director, Lung Cancer Research Program at SCRI, related to the recently approved immunotherapy drug, nivolumab. Nivolumab was investigated in a phase III study compared against the chemotherapy drug, docetaxel for relapsed patients with advanced stage squamous cell lung cancer. "As the leading cause of cancer death in the U.S., lung cancer continues to be a vital research area where more treatment options are needed," Spigel said. "We are encouraged to see an immunotherapy, which has improved survival rates and fewer side effects than chemotherapy, become a new standard of care for this population of patients." Several SCRI investigators are presenting noteworthy studies in oral sessions, which include:
The researchers represent SCRI's global network of strategic sites: SCRI at Tennessee Oncology, SCRI at HealthONE, SCRI - United Kingdom, Colorado Blood Cancer Institute, The Center for Cancer and Blood Disorders - Ft. Worth, SCRI at Florida Cancer Specialists & Research Institute, Leaders in Oncology Care (The LOC in London), The Stephenson Cancer Center at the University of Oklahoma and Oncology Hematology Care, Inc. About Sarah Cannon Research Institute Sarah Cannon Research Institute (SCRI) is the research arm of HCA's global cancer enterprise, Sarah Cannon. Focused on advancing therapies for patients, it is one of the world's leading clinical research organizations conducting community-based clinical trials in oncology, cardiology and orthopedics through affiliations with a network of more than 1,000 physicians across the United States and United Kingdom. SCRI has led more than 170 first-in-man clinical trials since its inception in 1993, and has been a clinical trial leader in nearly 80 percent of approved cancer therapies in the last 10 years. Additionally, SCRI offers management, regulatory, and other research support services for drug development and industry sponsors as well as strategic investigator sites through its contract research organization (CRO), SCRI Development Innovations. For more information, visit sarahcannon.com. View source version on businesswire.com: http://www.businesswire.com/news/home/20150521006370/en/ |